Promising combo offers new hope for elderly leukemia patients
NCT ID NCT03466294
First seen Apr 12, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study tested a combination of two drugs, azacitidine and venetoclax, as an initial treatment for adults aged 60 and older with acute myeloid leukemia (AML) who had not received prior therapy. Participants received the drugs together as induction therapy, and those who responded continued on venetoclax alone as maintenance. The goal was to see how long remission lasted and how many patients achieved a deep response with no detectable leukemia cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.